Zinc Ion

Zinc Ion

SCHEMBL3884322

CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/CCCCC(O)(O)C(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=CCCCCC(O)(O)C(=O)[O-].[Zn+2]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ABCC3 O15438 1/20 0.60
ABCC4 O15439 1/20 0.60
HMGCR P04035 6/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 1/20 0.55
PDE6D O43924 1/20 0.55
NR1I2 O75469 1/20 0.55
PDE4D Q08499 1/20 0.55
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19474869 0.97 ABCC3 (0.62) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL4150176 0.97 ABCC3 (0.62) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL4538040 0.97 ABCC3 (0.62) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL3887767 0.92 HMGCR (0.59) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL4538441 0.90 HMGCR (0.61) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL3305 0.88 ABCC3 (0.57) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL17635504 0.85 HMGCR (0.67) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL16401134 0.84 ABCC3 (0.53) ABCC3ABCC4HMGCRALDH1A1CYP3A4
Zinc Ion SCHEMBL1741829 0.82 ABCC3 (0.42) ABCC3ABCC4HMGCRALDH1A1CYP3A4
SCHEMBL3885922 0.81 HMGCR (0.62) ABCC3ABCC4HMGCRALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013188-B1 ROSUVASTATIN ZINC SALT EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÚKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2016-09-07 EP claimed
US-9174945-B2 Rosuvastatin zinc salt EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2015-11-03 US claimed
US-20090306117-A1 ROSUVASTATIN ZINC SALT EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2009-12-10 US claimed
EP-2013188-A1 ROSUVASTATIN ZINC SALT Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) 2009-01-14 EP claimed
WO-2007119085-A1 ROSUVASTATIN ZINC SALT EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MUKODO RESZVENYTÁRSASÁG (HU) 2007-10-25 WO claimed
EP-2013188-B1 ROSUVASTATIN ZINC SALT EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÚKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) 2016-09-07 EP disclosed
US-9174945-B2 Rosuvastatin zinc salt EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2015-11-03 US disclosed
US-20090306117-A1 ROSUVASTATIN ZINC SALT EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2009-12-10 US disclosed
EP-2013188-A1 ROSUVASTATIN ZINC SALT Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) 2009-01-14 EP disclosed
WO-2007119085-A1 ROSUVASTATIN ZINC SALT EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MUKODO RESZVENYTÁRSASÁG (HU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306117-A1 ROSUVASTATIN ZINC SALT SLC39A11, SLC39A3, SLC30A7 ABCC3 1943/4885ABCC4 2278/4885HMGCR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.